|
Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders. |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - GE Healthcare |
Consulting or Advisory Role - Celyad; Omniseq |
Research Funding - Alkermes; Altor BioScience; Bristol-Myers Squibb; Merck |
|
|
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); OncoMed (Inst) |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antonios Papanicolau-Sengos |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - OmniSeq |
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Patents, Royalties, Other Intellectual Property - OmniSeq |
|
|
Employment - OmniSeq; Thermo Fisher Scientific |
Leadership - OmniSeq; Thermo Fisher Scientific |
Stock and Other Ownership Interests - OmniSeq; Thermofisher Scientific Biomarkers |
|
|
|
|
Stock and Other Ownership Interests - OmniSeq |
Consulting or Advisory Role - NanoString Technologies; Quorum Consulting |
Patents, Royalties, Other Intellectual Property - OmniSeq |
Other Relationship - OmniSeq |